Ruo-Yu He
Overview
Explore the profile of Ruo-Yu He including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
73
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang Y, He R, Xu C, Li X, Cao Y
World J Gastroenterol
. 2024 Jan;
29(48):6222-6234.
PMID: 38186864
Background: Ulcerative colitis (UC) is a chronic gastrointestinal disorder characterized by inflammation and ulceration, representing a significant predisposition to colorectal cancer. Recent advances in single-cell RNA sequencing (scRNA-seq) technology offer...
2.
Pan X, Huang J, Liu S, Shao Y, Xi J, He R, et al.
Exp Ther Med
. 2023 Oct;
26(5):516.
PMID: 37854499
Globally, liver cancer ranks among the most lethal cancers, with chemotherapy being one of its primary treatments. However, poor selectivity, systemic toxicity, a narrow treatment window, low response rate and...
3.
Xi J, Cao Y, He R, Zhang J, Zhao Y, Tong Q, et al.
Drug Des Devel Ther
. 2023 Jul;
17:2063-2076.
PMID: 37457888
Objective: Silibinin, a natural product extracted from the seeds of the , is versatile with various pharmacological effects. However, its clinical application was strongly hampered by its low bioavailability and...
4.
Xi J, He R, Zhang J, Cai Z, Zhuang R, Zhao Y, et al.
Arch Pharm (Weinheim)
. 2019 Jul;
352(8):e1900024.
PMID: 31338897
A series of novel 3-(thiophen-2-ylthio)pyridine derivatives as insulin-like growth factor 1 receptor (IGF-1R) inhibitors was designed and synthesized. IGF-1R kinase inhibitory activities and cytotoxicities against HepG2 and WSU-DLCL2 cell lines...
5.
Lin H, Cheng Z, He R, Song L, Tian M, Zhou L, et al.
Cancer Res
. 2016 Oct;
76(23):6924-6936.
PMID: 27758890
Fatty acid synthase (FASN) is the terminal enzyme in de novo lipogenesis and plays a key role in cell proliferation. Pharmacologic inhibitors of FASN are being evaluated in clinical trials...